Insulet Corporation stock hits 52-week low at $216.12

Insulet Corporation stock reached a new 52-week low, touching $216.12 amid a challenging year for the company. The decline has accelerated recently, with shares down over 30% in the past six months. Despite this downturn, InvestingPro data reveals the company remains profitable with impressive revenue growth of 30.73% over the last twelve months, while 10 analysts have recently revised their earnings estimates upward for the upcoming period. This marks a notable downturn for the company, which has faced various market pressures and competitive challenges. Yet InvestingPro analysis suggests the stock may be undervalued at current levels. Investors seeking deeper insights can access 10 additional ProTips and a comprehensive Pro Research Report on PODD, transforming complex data into actionable intelligence.

In other recent news, Insulet Corporation reported impressive fourth-quarter revenue figures, reaching $783.8 million, marking a 31.2% increase year-over-year in constant currency. This performance surpassed both Canaccord Genuity’s estimate of $772.5 million and the consensus expectation of $769.0 million. Additionally, BTIG reiterated its Buy rating and maintained a $380.00 price target, highlighting the strong quarterly results. However, Insulet initiated a voluntary recall of specific Omnipod 5 Pods due to a manufacturing issue that could cause insulin leakage, potentially impacting blood glucose levels.

On the analyst front, Bernstein SocGen Group lowered its price target for Insulet to $330 from $380, citing competition concerns from Tandem Diabetes Care and Medtronic. Similarly, Oppenheimer adjusted its price target to $300 from $365 following the company’s recent earnings and fiscal 2026 guidance. Despite these adjustments, both firms maintained an Outperform rating on the stock. Canaccord Genuity also revised its price target to $435 from $450, while keeping a Buy rating, due to valuation considerations. These developments reflect a mix of strong financial performance and competitive pressures facing Insulet.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.